U. Egerland

发表

Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.

Sally Wagner, M. Scheunemann, Karolin Dipper, 2016, European journal of medicinal chemistry.

Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.

U. Egerland, N. Hoefgen, M. Malamas, 2011, Journal of medicinal chemistry.

5-(4-Hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-7-phenyl-2,3,6,7-tetrahydro-1,4-thiazepines as compounds with high affinity at the benzodiazepine binding site on GABA(A) receptors.

U. Egerland, R. Schindler, C. Grunwald, 2011, Die Pharmazie.

Anti-Inflammatory Potential of the Selective Phosphodiesterase 4 Inhibitor N-(3,5-Dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), in Human Cell Preparations

U. Egerland, C. Rundfeldt, R. Draheim, 2004, Journal of Pharmacology and Experimental Therapeutics.

Refolding, purification, and characterization of human recombinant PDE4A constructs expressed in Escherichia coli.

U. Egerland, T. Kronbach, R. Rudolph, 2000, Protein expression and purification.

Investigation of an 18F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2A

M. Scheunemann, U. Egerland, J. Steinbach, 2018, Molecules.

Investigation of an 18 F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2 A

M. Scheunemann, U. Egerland, J. Steinbach, 2018 .

Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test

U. Egerland, N. Hoefgen, H. Stange, 2012, Psychopharmacology.

New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity.

U. Egerland, H. Lankau, C. Grunwald, 2007, European journal of medicinal chemistry.

Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors.

U. Egerland, H. Lankau, C. Grunwald, 2006, Journal of medicinal chemistry.

Fluorine‐Containing 6,7‐Dialkoxybiaryl‐Based Inhibitors for Phosphodiesterase 10 A: Synthesis and in vitro Evaluation of Inhibitory Potency, Selectivity, and Metabolism

M. Scheunemann, U. Egerland, P. Brust, 2014, ChemMedChem.

Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography

M. Scheunemann, U. Egerland, J. Steinbach, 2015, Molecules.

Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.

Christian Grunwald, Ute Egerland, U. Egerland, 2010, Journal of medicinal chemistry.

Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

T. Comery, U. Egerland, M. Malamas, 2009, Journal of Pharmacology and Experimental Therapeutics.

Phosphodiesterase 10 A Inhibitor Activity in Preclinical Models of the Positive , Cognitive , and Negative Symptoms of Schizophrenia

T. Comery, U. Egerland, M. Malamas, 2009 .

Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test

U. Egerland, N. Hoefgen, H. Stange, 2011, Psychopharmacology.

Discovery of triazines as potent, selective and orally active PDE4 inhibitors.

U. Egerland, C. Grunwald, R. Gewald, 2013, Bioorganic & medicinal chemistry letters.

New 5-aminoacyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones with antiarrhythmic activity.

U. Egerland, N. V. Kaverina, C. Rüger, 1997, Die Pharmazie.

1,5‐Disubstituted Indazol‐3‐ols with Anti‐Inflammatory Activity

U. Egerland, R. Schindler, I. Szelenyi, 1998, Archiv der Pharmazie.

Phosphodiesterase 2 Inhibitors Promote Axonal Outgrowth in Organotypic Slice Co-Cultures

U. Egerland, T. Hage, N. Scherf, 2012, Neurosignals.

Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.

U. Egerland, N. Hoefgen, C. Grunwald, 2011, Bioorganic & medicinal chemistry letters.

Novel triazines as potent and selective phosphodiesterase 10A inhibitors.

U. Egerland, N. Hoefgen, M. Malamas, 2012, Bioorganic & medicinal chemistry letters.

Radiosynthesis and biological evaluation of the new PDE10A radioligand [18 F]AQ28A.

Sally Wagner, M. Scheunemann, U. Egerland, 2017, Journal of labelled compounds & radiopharmaceuticals.

Characterization in Rats of the Anxiolytic Potential of ELB139 [1-(4-Chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a New Agonist at the Benzodiazepine Binding Site of the GABAA Receptor

U. Egerland, B. Langen, K. Unverferth, 2005, Journal of Pharmacology and Experimental Therapeutics.

Large-Scale Mining for Similar Protein Binding Pockets: With RAPMAD Retrieval on the Fly Becomes Real

Timo Krotzky, Christian Grunwald, Ute Egerland, 2015, J. Chem. Inf. Model..

Novel triazines as potent and selective phosphodiesterase 10A inhibitors.

U. Egerland, N. Hoefgen, M. Malamas, 2012, Bioorganic & medicinal chemistry letters.

[Synthesis of substituted 6-phenylpyrazolo[3,4-d]pyrimidines with potential adenosin-A2A antagonistic activity].

U. Egerland, K. Unverferth, R. Aurich, 2005, Die Pharmazie.